Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate

Objectives Long-term safety and efficacy of adalimumab among patients with juvenile idiopathic arthritis (JIA) was evaluated through 6 years of treatment.Methods Children aged 4–17 years with polyarticular JIA were enrolled in a phase III, randomised-withdrawal, double-blind, placebo-controlled tria...

Full description

Bibliographic Details
Main Authors: Hermine I Brunner, Carine Wouters, Daniel J Lovell, Nicolino Ruperto, Andreas O Reiff, Lawrence Jung, Katerina Jarosova, Dana Němcová, Richard Mouy, Christy Sandborg, John F Bohnsack, Christos Gabriel, Gloria Higgins, Olcay Y Jones, Veronika Vargová, Elizabeth Chalom, Yanna Song
Format: Article
Language:English
Published: BMJ Publishing Group 2020-08-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/6/2/e001208.full

Internet

https://rmdopen.bmj.com/content/6/2/e001208.full

Similar Items